# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $33 price target.
Piper Sandler analyst Biren Amin maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $27 to ...
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.39) by...
Under the terms of the agreement, Nectin granted Immunome an exclusive, worldwide, all-fields license to monoclonal antibodies ...
Piper Sandler analyst Biren Amin initiates coverage on Immunome (NASDAQ:IMNM) with a Overweight rating and announces Price T...